Palovarotene dose level 2    (DrugBank: Palovarotene)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
272進行性骨化性線維異形成症2

272. 進行性骨化性線維異形成症 [臨床試験数:23,薬物数:21(DrugBank:4),標的遺伝子数:10,標的パスウェイ数:87
Searched query = "Fibrodysplasia ossificans progressiva", "FOP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 23 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02979769
(ClinicalTrials.gov)
November 28, 201623/11/2016An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in FOP Subjects in FranceA Phase 2, Open-Label Extension, Efficacy and Safety Study of a RAR?-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)Fibrodysplasia Ossificans ProgressivaDrug: Palovarotene dose level 1;Drug: Palovarotene dose level 2Clementia Pharmaceuticals Inc.NULLActive, not recruiting6 Years65 YearsAll9Phase 2France
2NCT02279095
(ClinicalTrials.gov)
October 27, 201426/10/2014An Open-Label Extension Study of Palovarotene Treatment in FOPA Phase 2, Open-Label Extension, Efficacy and Safety Study of a RAR? Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)Fibrodysplasia Ossificans ProgressivaDrug: Palovarotene dose level 1;Drug: Palovarotene dose level 2;Drug: Palovarotene dose level 3;Drug: Palovarotene dose level 4Clementia Pharmaceuticals Inc.NULLActive, not recruiting6 Years65 YearsAll54Phase 2United States;Argentina;Australia;France;United Kingdom